id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0583-0016,FDA,FDA-2011-N-0583,"Clarification of Orphan-Drug Exclusivity Following Catalyst Pharms., Inc. v. Becerra; Notification",Rule,Approval,2023-01-24T05:00:00Z,2023,1,2023-01-24T05:00:00Z,,2023-01-24T17:14:45Z,2023-01179,0,0,0900006485606066
FDA-2011-N-0583-0015,FDA,FDA-2011-N-0583,Policy on Orphan-Drug Exclusivity Clarification,Rule,Correction,2014-12-23T05:00:00Z,2014,12,2014-12-23T05:00:00Z,,2014-12-23T14:44:06Z,2014-29920,0,0,090000648198e7cb
FDA-2011-N-0583-0014,FDA,FDA-2011-N-0583,Orphan Drug Regulations,Rule,Final Rule,2013-06-12T04:00:00Z,2013,6,2013-06-12T04:00:00Z,,2014-12-05T18:02:06Z,2013-13930,0,0,090000648131aea2
FDA-2011-N-0583-0001,FDA,FDA-2011-N-0583,Orphan Drug Regulations,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2011-10-19T04:00:00Z,2011,10,2011-10-19T04:00:00Z,2012-01-18T04:59:59Z,2011-10-19T20:37:45Z,2011-27037,0,0,0900006480f55c83